PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 10/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. RVPH, JSPR, LVTX, VRCA, ANVS, BTAI, XLO, OKUR, DYAI, and ELUTShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Reviva Pharmaceuticals (RVPH), Jasper Therapeutics (JSPR), LAVA Therapeutics (LVTX), Verrica Pharmaceuticals (VRCA), Annovis Bio (ANVS), BioXcel Therapeutics (BTAI), Xilio Therapeutics (XLO), OnKure Therapeutics (OKUR), Dyadic International (DYAI), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Reviva Pharmaceuticals Jasper Therapeutics LAVA Therapeutics Verrica Pharmaceuticals Annovis Bio BioXcel Therapeutics Xilio Therapeutics OnKure Therapeutics Dyadic International Elutia PHAXIAM Therapeutics (NASDAQ:PHXM) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings. Do analysts prefer PHXM or RVPH? Reviva Pharmaceuticals has a consensus target price of $4.86, indicating a potential upside of 772.02%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Reviva Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media refer more to PHXM or RVPH? In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Reviva Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Overall Sentiment PHAXIAM Therapeutics Neutral Reviva Pharmaceuticals Neutral Do institutionals & insiders have more ownership in PHXM or RVPH? 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, PHXM or RVPH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM TherapeuticsN/AN/A-$240KN/AN/AReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.86 Is PHXM or RVPH more profitable? Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Reviva Pharmaceuticals N/A N/A -259.17% Which has more volatility and risk, PHXM or RVPH? PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. SummaryReviva Pharmaceuticals beats PHAXIAM Therapeutics on 6 of the 9 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$220.71M$6.16B$10.66BDividend YieldN/A3.81%5.72%4.86%P/E RatioN/A3.2829.5428.34Price / SalesN/A5,394.57577.73128.29Price / CashN/A13.1937.1261.42Price / Book0.3992.8612.066.50Net Income-$240K-$90.99M$3.32B$276.64M7 Day PerformanceN/A0.26%-0.48%-0.11%1 Month PerformanceN/A5.99%5.54%1.39%1 Year PerformanceN/A614.29%65.53%32.46% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049RVPHReviva Pharmaceuticals3.0433 of 5 stars$0.57-2.2%$4.86+745.3%-69.3%$40.74MN/A-0.885Options VolumeJSPRJasper Therapeutics3.1135 of 5 stars$2.45-1.2%$25.63+945.9%-88.0%$40.31MN/A-0.4120LVTXLAVA Therapeutics1.7266 of 5 stars$1.48-2.6%$2.69+81.4%-6.3%$39.98M$11.98M-1.4160Insider TradeHigh Trading VolumeVRCAVerrica Pharmaceuticals3.8971 of 5 stars$4.15-1.9%$60.00+1,345.8%-75.4%$39.96M$7.57M-0.5040ANVSAnnovis Bio2.6602 of 5 stars$1.99-2.2%$17.33+773.2%-78.8%$39.56MN/A-0.973BTAIBioXcel Therapeutics4.0137 of 5 stars$2.31-6.1%$39.75+1,620.8%-76.2%$39.38M$2.27M-0.1890Positive NewsXLOXilio Therapeutics1.5296 of 5 stars$0.74-2.0%$3.00+303.7%-22.1%$39.29M$15.00M-0.9870OKUROnKure Therapeutics3.4102 of 5 stars$2.78-3.5%$32.33+1,063.1%-84.6%$38.97MN/A-0.58N/ADYAIDyadic International2.3296 of 5 stars$1.07+1.9%$6.00+460.7%-2.7%$38.72M$3.42M-5.637News CoverageNegative NewsAnalyst ForecastShort Interest ↑Gap UpELUTElutia2.6665 of 5 stars$0.89-1.0%$7.00+685.9%-72.6%$38.16M$24.38M-0.84180 Related Companies and Tools Related Companies Reviva Pharmaceuticals Competitors Jasper Therapeutics Competitors LAVA Therapeutics Competitors Verrica Pharmaceuticals Competitors Annovis Bio Competitors BioXcel Therapeutics Competitors Xilio Therapeutics Competitors OnKure Therapeutics Competitors Dyadic International Competitors Elutia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts